T helper type 17 in psoriasis: From basic immunology to clinical practice

Dermatologica Sinica

Volumn 30, Issue 4, 2012, Pages 136-141

  Chiu, Hsien Yi ^a   Cheng, Yu Pin ^a   Tsai, Tsen Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

biologics; interleukin 17; interleukin 23; psoriasis; T helper type 17

Indexed keywords

BRODALUMAB; CYCLOSPORIN A; ETANERCEPT; ETRETIN; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23; INTERLEUKIN 23 ANTIBODY; IXEKIZUMAB; METHOTREXATE; PLACEBO; SECUKINUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CLINICAL PRACTICE; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMMUNE RESPONSE; INFECTION; LATENT TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; SKIN CANCER; TH17 CELL;

EID: 84870888397     PISSN: 10278117     EISSN: 2223330X     Source Type: Journal    
DOI: 10.1016/j.dsi.2012.08.002     Document Type: Review

References (103)

1. T.R. Mosmann, H. Cherwinski, M.W. Bond, M.A. Giedlin, and R.L. Coffman Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins J Immunol 136 1986 2348 2357 (Pubitemid 16136806)
2. L.E. Harrington, R.D. Hatton, and P.R. Mangan Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages Nat Immunol 6 2005 1123 1132 (Pubitemid 41541790)
3. E. Rouvier, M.F. Luciani, M.G. Mattei, F. Denizot, and P. Golstein CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene J Immunol 150 1993 5445 5456 (Pubitemid 23180658)
4. B. Oppmann, R. Lesley, and B. Blom Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 Immunity 13 2000 715 725
5. C.L. Langrish, Y. Chen, and W.M. Blumenschein IL-23 drives a pathogenic T cell population that induces autoimmune inflammation J Exp Med 201 2005 233 240 (Pubitemid 40189432)
6. C. Infante-Duarte, H.F. Horton, M.C. Byrne, and T. Kamradt Microbial lipopeptides induce the production of IL-17 in Th cells J Immunol 165 2000 6107 6115
7. H. Park, Z. Li, and X.O. Yang A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 Nat Immunol 6 2005 1133 1141 (Pubitemid 41541791)
8. C. Dong TH17 cells in development: an updated view of their molecular identity and genetic programming Nat Rev Immunol 8 2008 337 348 (Pubitemid 351595217)
9. C.A. Murphy, C.L. Langrish, and Y. Chen Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation J Exp Med 198 2003 1951 1957 (Pubitemid 38032126)
10. A. Di Cesare, P. Di Meglio, and F.O. Nestle The IL-23/Th17 axis in the immunopathogenesis of psoriasis J Invest Dermatol 129 2009 1339 1350
11. S. Aggarwal, N. Ghilardi, M.H. Xie, F.J. de Sauvage, and A.L. Gurney Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17 J Biol Chem 278 2003 1910 1914 (Pubitemid 36801431)
12. R.J. Hinton Effect of condylotomy on matrix synthesis and mineralization in the rat mandibular condylar cartilage Arch Oral Biol 34 1989 1003 1009
13. M. Veldhoen, R.J. Hocking, C.J. Atkins, R.M. Locksley, and B. Stockinger TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells Immunity 24 2006 179 189 (Pubitemid 43214587)
14. P.R. Mangan, L.E. Harrington, and D.B. O'Quinn Transforming growth factor-beta induces development of the T(H)17 lineage Nature 441 2006 231 234
15. N.J. Wilson, K. Boniface, and J.R. Chan Development, cytokine profile and function of human interleukin 17-producing helper T cells Nat Immunol 8 2007 950 957 (Pubitemid 47300009)
16. I.I. Ivanov, B.S. McKenzie, and L. Zhou The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17 + T helper cells Cell 126 2006 1121 1133 (Pubitemid 44380299)
17. X.O. Yang, B.P. Pappu, and R. Nurieva T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma Immunity 28 2008 29 39
18. L. Zhou, I.I. Ivanov, and R. Spolski IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways Nat Immunol 8 2007 967 974 (Pubitemid 47300011)
19. X.O. Yang, A.D. Panopoulos, and R. Nurieva STAT3 regulates cytokine-mediated generation of inflammatory helper T cells J Biol Chem 282 2007 9358 9363 (Pubitemid 47104613)
20. R. Nurieva, X.O. Yang, and G. Martinez Essential autocrine regulation by IL-21 in the generation of inflammatory T cells Nature 448 2007 480 483 (Pubitemid 47123514)
21. A. Brustle, S. Heink, and M. Huber The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4 Nat Immunol 8 2007 958 966 (Pubitemid 47300010)
22. F. Zhang, G. Meng, and W. Strober Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells Nat Immunol 9 2008 1297 1306
23. B.U. Schraml, K. Hildner, and W. Ise The AP-1 transcription factor Batf controls T(H)17 differentiation Nature 460 2009 405 409
24. Y. Iwakura, H. Ishigame, S. Saijo, and S. Nakae Functional specialization of interleukin-17 family members Immunity 34 2011 149 162
25. H.C. Shin, N. Benbernou, S. Esnault, and M. Guenounou Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway Cytokine 11 1999 257 266 (Pubitemid 29213172)
26. S. Hamada, M. Umemura, and T. Shiono IL-17A produced by gammadelta T cells plays a critical role in innate immunity against listeria monocytogenes infection in the liver J Immunol 181 2008 3456 3463
27. A.V. Rachitskaya, A.M. Hansen, and R. Horai Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion J Immunol 180 2008 5167 5171
28. H. Stepanova, M. Mensikova, K. Chlebova, and M. Faldyna CD4+ and gammadeltaTCR+ T lymphocytes are sources of interleukin-17 in swine Cytokine 58 2012 152 157
29. J. Noh, and G. Noh Allergen-specific responses of CD19high and CD19low B cells in non-IgE-mediated food allergy of late eczematous reactions in atopic dermatitis: presence of IL-17- and IL-32-producing regulatory B cells (Br17 & Br32) Inflamm Allergy Drug Targets 11 2012 320 329
30. S. Kagami, H.L. Rizzo, S.E. Kurtz, L.S. Miller, and A. Blauvelt IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol 185 2010 5453 5462
31. K.I. Happel, P.J. Dubin, and M. Zheng Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae J Exp Med 202 2005 761 769 (Pubitemid 41345965)
32. T. Korn, E. Bettelli, M. Oukka, and V.K. Kuchroo IL-17 and Th17 cells Annu Rev Immunol 27 2009 485 517
33. K.V. Arun, A. Talwar, and T.S. Kumar T-helper cells in the etiopathogenesis of periodontal disease: a mini review J Indian Soc Periodontol 15 2011 4 10
34. M.B. Teunissen, C.W. Koomen, R. de Waal Malefyt, E.A. Wierenga, and J.D. Bos Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes J Invest Dermatol 111 1998 645 649 (Pubitemid 28452327)
35. C. Johansen, P.A. Usher, R.B. Kjellerup, D. Lundsgaard, L. Iversen, and K. Kragballe Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin Br J Dermatol 160 2009 319 324
36. S. Kagami, H.L. Rizzo, J.J. Lee, Y. Koguchi, and A. Blauvelt Circulating Th17, Th22, and Th1 cells are increased in psoriasis J Invest Dermatol 130 2010 1373 1383
37. J.R. Chan, W. Blumenschein, and E. Murphy IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis J Exp Med 203 2006 2577 2587 (Pubitemid 44833335)
38. E. Lee, W.L. Trepicchio, and J.L. Oestreicher Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris J Exp Med 199 2004 125 130 (Pubitemid 38076484)
39. L.C. Zaba, J. Fuentes-Duculan, and N.J. Eungdamrong Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells J Invest Dermatol 129 2009 79 88
40. E.V. Acosta-Rodriguez, L. Rivino, and J. Geginat Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells Nat Immunol 8 2007 639 646 (Pubitemid 46785128)
41. A. Strange, F. Capon, and C.C. Spencer A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1 Nat Genet 42 2010 985 990
42. D.A. Martin, J.E. Towne, and G. Kricorian The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings J Invest Dermatol 2012 10.1038/jid.2012.194 [Epub ahead of print]
43. T. Korn, E. Bettelli, and W. Gao IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells Nature 448 2007 484 487 (Pubitemid 47123515)
44. W.J. Leonard, and R. Spolski Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation Nat Rev Immunol 5 2005 688 698 (Pubitemid 43086171)
45. I. Gutcher, M.K. Donkor, Q. Ma, A.Y. Rudensky, R.A. Flavell, and M.O. Li Autocrine transforming growth factor-beta1 promotes in vivo Th17 cell differentiation Immunity 34 2011 396 408
46. E. Fitch, E. Harper, I. Skorcheva, S.E. Kurtz, and A. Blauvelt Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines Curr Rheumatol Rep 9 2007 461 467 (Pubitemid 350305203)
47. C. Ortega, A.S. Fernandez, and J.M. Carrillo IL-17-producing CD8 + T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines J Leukoc Biol 86 2009 435 443
48. F. Annunziato, L. Cosmi, and V. Santarlasci Phenotypic and functional features of human Th17 cells J Exp Med 204 2007 1849 1861 (Pubitemid 47240944)
49. P.C. Res, G. Piskin, and O.J. de Boer Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis PLoS One 5 2010 e14108
50. S. Eyerich, K. Eyerich, and D. Pennino Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling J Clin Invest 119 2009 3573 3585
51. T. Duhen, R. Geiger, D. Jarrossay, A. Lanzavecchia, and F. Sallusto Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells Nat Immunol 10 2009 857 863
52. S. Trifari, C.D. Kaplan, E.H. Tran, N.K. Crellin, and H. Spits Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells Nat Immunol 10 2009 864 871
53. H. Fujita, K.E. Nograles, T. Kikuchi, J. Gonzalez, J.A. Carucci, and J.G. Krueger Human Langerhans cells induce distinct IL-22-producing CD4 + T cells lacking IL-17 production Proc Natl Acad Sci U S A 106 2009 21795 21800
54. S. Hori, T. Nomura, and S. Sakaguchi Control of regulatory T cell development by the transcription factor Foxp3 Science 299 2003 1057 1061 (Pubitemid 36222930)
55. S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono Regulatory T cells and immune tolerance Cell 133 2008 775 787 (Pubitemid 351707693)
56. D. Mucida, Y. Park, and G. Kim Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid Science 317 2007 256 260 (Pubitemid 47076203)
57. A. Laurence, C.M. Tato, and T.S. Davidson Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation Immunity 26 2007 371 381 (Pubitemid 46413906)
58. L.Y. Sender, K. Gibbert, Y. Suezer, H.H. Radeke, U. Kalinke, and Z. Waibler CD40 ligand-triggered human dendritic cells mount interleukin-23 responses that are further enhanced by danger signals Mol Immunol 47 2010 1255 1261
59. L. Zhou, J.E. Lopes, and M.M. Chong TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function Nature 453 2008 236 240 (Pubitemid 351667978)
60. J. Du, C. Huang, B. Zhou, and S.F. Ziegler Isoform-specific inhibition of ROR alpha-mediated transcriptional activation by human FOXP3 J Immunol 180 2008 4785 4792
61. K. Ichiyama, H. Yoshida, and Y. Wakabayashi Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat J Biol Chem 283 2008 17003 17008
62. H.J. Bovenschen, P.C. van de Kerkhof, P.E. van Erp, R. Woestenenk, I. Joosten, and H.J. Koenen Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin J Invest Dermatol 131 2011 1853 1860
63. F. Osorio, S. LeibundGut-Landmann, and M. Lochner DC activated via dectin-1 convert Treg into IL-17 producers Eur J Immunol 38 2008 3274 3281
64. K.S. Voo, Y.H. Wang, and F.R. Santori Identification of IL-17-producing FOXP3+ regulatory T cells in humans Proc Natl Acad Sci U S A 106 2009 4793 4798
65. X.O. Yang, R. Nurieva, and G.J. Martinez Molecular antagonism and plasticity of regulatory and inflammatory T cell programs Immunity 29 2008 44 56
66. F. Deknuydt, G. Bioley, D. Valmori, and M. Ayyoub IL-1beta and IL-2 convert human Treg into T(H)17 cells Clin Immunol 131 2009 298 307
67. G. Wei, L. Wei, and J. Zhu Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4 + T cells Immunity 30 2009 155 167
68. F.O. Nestle, D.H. Kaplan, and J. Barker Psoriasis. N Engl J Med 361 2009 496 509
69. L.C. Zaba, I. Cardinale, and P. Gilleaudeau Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses J Exp Med 204 2007 3183 3194
70. L.C. Zaba, M. Suarez-Farinas, and J. Fuentes-Duculan Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes J Allergy Clin Immunol 124 2009 1022-10. e1-395
71. M.J. Ruddy, G.C. Wong, and X.K. Liu Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members J Biol Chem 279 2004 2559 2567 (Pubitemid 38114241)
72. M.J. Ruddy, F. Shen, J.B. Smith, A. Sharma, and S.L. Gaffen Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment J Leukoc Biol 76 2004 135 144 (Pubitemid 38857180)
73. A. Chiricozzi, E. Guttman-Yassky, and M. Suarez-Farinas Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis J Invest Dermatol 131 2011 677 687
74. M. Caproni, E. Antiga, L. Melani, W. Volpi, E. Del Bianco, and P. Fabbri Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial J Clin Immunol 29 2009 210 214
75. C. Yue, X. You, and L. Zhao The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients Rheumatol Int 30 2010 1553 1557
76. P. Quaglino, M. Bergallo, and R. Ponti Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response Dermatology 223 2011 57 67
77. E. Racz, E.P. Prens, and D. Kurek Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways J Invest Dermatol 131 2011 1547 1558
78. S. Coimbra, H. Oliveira, and F. Reis Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-alpha levels in patients with psoriasis before, during and after psoralen - ultraviolet A and narrowband ultraviolet B therapy Br J Dermatol 163 2010 1282 1290
79. A.S. Haider, M.A. Lowes, and M. Suarez-Farinas Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis J Immunol 180 2008 1913 1920
80. M.A. Lowes, T. Kikuchi, and J. Fuentes-Duculan Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells J Invest Dermatol 128 2008 1207 1211 (Pubitemid 351543220)
81. Y. Kageyama, H. Kobayashi, and N. Kato Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis Mod Rheumatol 19 2009 657 662
82. J. Meephansan, K. Ruchusatsawat, W. Sindhupak, P.S. Thorner, and J. Wongpiyabovorn Effect of methotrexate on serum levels of IL-22 in patients with psoriasis Eur J Dermatol 21 2011 501 504
83. C.L. Leonardi, A.B. Kimball, and K.A. Papp Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674 (Pubitemid 351671883)
84. K.A. Papp, R.G. Langley, and M. Lebwohl Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684 (Pubitemid 351671884)
85. K. Reich, K.A. Papp, and C.E. Griffiths An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up J Drugs Dermatol 11 2012 300 312
86. A.B. Kimball, K.B. Gordon, and S. Fakharzadeh Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years Br J Dermatol 166 2012 861 872
87. K. Papp, A. Kimball, and Y. Wasfi Long-term efficacy and safety of ustekinumab in patients with moderate to severe psoriasis through 5 years of follow-up: results from the PHOENIX 1 long-term extension (Poster P14-34). Paper presented at the 2nd Eastern Asia Dermatology Congress June 2012 China Beijing 13-15
88. T.F. Tsai, J.C. Ho, and M. Song Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL) J Dermatol Sci 63 2011 154 163
89. T.S. Wang, and T.F. Tsai Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series J Dermatol 38 2011 1096 1099
90. H.Y. Chiu, P.Y. Huang, and S.H. Jee HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis Br J Dermatol 166 2012 288 297
91. C.E. Griffiths, B.E. Strober, and P. van de Kerkhof Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 362 2010 118 128
92. L. van der Fits, S. Mourits, and J.S. Voerman Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis J Immunol 182 2009 5836 5845
93. Papp KA. Secukinumab efficacy and safety preliminary results from a phase II subcutaneous dose-ranging study in the treatment of moderate-to-severe plaque psoriasis (oral presentation FC01.5). Paper presented at the 20th Congress of the European Academy of Dermatology and Venereology, Lisbon, Portugal; 20-24 October 2011.
94. Papp KA. Secukinumab, a novel fully human antibody to interleukin-17A in the treatment of moderate-to-severe plaque psoriasis: efficacy and safety interim results from a phase II intravenous induction dose-ranging study (oral presentation FC01.7). Paper presented at the 20th Congress of the European Academy of Dermatology and Venereology; 20-24 October 2011.
95. Rich PA. Secukinumab, a new fully human monoclonal anti-interleukin-17A antibody, in the treatment of moderate-to-severe plaque psoriasis: interim efficacy and safety data from a phase II regimen-finding trial (oral presentation FC01.6). Paper presented at the 20th Congress of the European Academy of Dermatology and Venereology, Lisbon, Portugal; 20-24 October 2011.
96. C. Leonardi, R. Matheson, and C. Zachariae Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis N Engl J Med 366 2012 1190 1199
97. K.A. Papp, C. Leonardi, and A. Menter Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis N Engl J Med 366 2012 1181 1189
98. M.A. Gardam, E.C. Keystone, and R. Menzies Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management Lancet Infect Dis 3 2003 148 155 (Pubitemid 36278124)
99. ®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan Br J Dermatol 164 2011 553 559
100. T.F. Tsai, V. Ho, and M. Song The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection Br J Dermatol 2012 10.1111/j.1365-2133.2012.11142.x [Epub ahead of print]
101. Y. Zheng, D.M. Danilenko, and P. Valdez Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis Nature 445 2007 648 651 (Pubitemid 46232884)
102. K. Wolk, S. Kunz, E. Witte, M. Friedrich, K. Asadullah, and R. Sabat IL-22 increases the innate immunity of tissues Immunity 21 2004 241 254 (Pubitemid 39094053)
103. E. Bettelli, T. Korn, and V.K. Kuchroo Th17: the third member of the effector T cell trilogy Curr Opin Immunol 19 2007 652 657 (Pubitemid 350236805)